Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana.
Identifieur interne : 000464 ( Ncbi/Merge ); précédent : 000463; suivant : 000465Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana.
Auteurs : Kwamena William Coleman Sagoe [Ghana] ; Afrakoma Adjoa Agyei ; Francesca Ziga ; Margaret Lartey [Ghana] ; Theophilus K. Adiku ; Makafui Seshi ; Max Q. Arens ; Julius Abraham Addo MingleSource :
- Journal of medical virology [ 1096-9071 ] ; 2012.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Agents antiVIH (administration et posologie), Anticorps de l'hépatite C (sang), Antigènes de surface du virus de l'hépatite B (sang), Charge virale, Co-infection (épidémiologie), Comorbidité, Femelle, Ghana, Humains, Hépatite B (), Hépatite B (épidémiologie), Hépatite C (), Hépatite C (épidémiologie), Immunoglobuline M (sang), Infections à VIH (), Infections à VIH (traitement médicamenteux), Infections à VIH (virologie), Mâle, Numération des lymphocytes CD4, Thérapie antirétrovirale hautement active (), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (isolement et purification).
- MESH :
- administration et posologie : Agents antiVIH.
- isolement et purification : VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- sang : Anticorps de l'hépatite C, Antigènes de surface du virus de l'hépatite B, Immunoglobuline M.
- traitement médicamenteux : Infections à VIH.
- virologie : Infections à VIH.
- épidémiologie : Co-infection, Hépatite B, Hépatite C.
- Adulte, Adulte d'âge moyen, Charge virale, Comorbidité, Femelle, Ghana, Humains, Hépatite B, Hépatite C, Infections à VIH, Mâle, Numération des lymphocytes CD4, Thérapie antirétrovirale hautement active.
- Wicri :
- geographic : Ghana.
English descriptors
- KwdEn :
- Adult, Anti-HIV Agents (administration & dosage), Antiretroviral Therapy, Highly Active (methods), CD4 Lymphocyte Count, Coinfection (epidemiology), Comorbidity, Female, Ghana, HIV Infections (complications), HIV Infections (drug therapy), HIV Infections (virology), HIV-1 (isolation & purification), Hepatitis B (complications), Hepatitis B (epidemiology), Hepatitis B Surface Antigens (blood), Hepatitis C (complications), Hepatitis C (epidemiology), Hepatitis C Antibodies (blood), Humans, Immunoglobulin M (blood), Male, Middle Aged, Viral Load.
- MESH :
- chemical , administration & dosage : Anti-HIV Agents.
- chemical , blood : Hepatitis B Surface Antigens, Hepatitis C Antibodies, Immunoglobulin M.
- geographic : Ghana.
- complications : HIV Infections, Hepatitis B, Hepatitis C.
- drug therapy : HIV Infections.
- epidemiology : Coinfection, Hepatitis B, Hepatitis C.
- isolation & purification : HIV-1.
- methods : Antiretroviral Therapy, Highly Active.
- virology : HIV Infections.
- Adult, CD4 Lymphocyte Count, Comorbidity, Female, Humans, Male, Middle Aged, Viral Load.
Abstract
Data on the effects of the presence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients co-infected with these viruses and HIV in West Africa are conflicting and little information is available in Ghana. A cohort of 138 treatment naïve individuals infected with HIV was screened for HBV and HCV serologic markers; HBsAg positive patients were tested for HBeAg, anti-HBe, and anti-HBc IgM. The viral load of HIV-1 in the plasma was determined in 81 patients. Eighteen of the 138 patients (13%) and 5 (3.6%) had HBsAg and anti-HCV, respectively. None of the patients had anti-HBc IgM, but 10 (55.6%) and 8 (44.4%) of the 18 patients who were HBsAg positive had HBeAg and anti-HBe, respectively. In patients with measurement of CD4(+) undertaken within 1 month (n = 83), CD4(+) count was significantly lower in patients with HBeAg (median [IQR], 81 [22-144]) as compared to those with anti-HBe (median [IQR], 210 [197-222]) (P = 0.002, CI: -96.46 to 51.21). However, those with HIV mono-infection had similar CD4(+) counts (median [IQR], 57 [14-159]) compared to those with HBeAg (P = 1.0, CI: -71.75 to 73.66). Similar results were obtained if CD4(+) count was measured within 2 months prior to initiation of HAART (n = 119). Generally, HBV and anti-HCV did not affect CD4(+) and viral loads of HIV-1 in plasma but patients with HIV and HBV co-infection who had HBeAg had more severe immune suppression as compared to those with anti-HBe. This may have implication for initiating HAART in HBV endemic areas.
DOI: 10.1002/jmv.22262
PubMed: 22095533
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000121
- to stream PubMed, to step Curation: 000121
- to stream PubMed, to step Checkpoint: 000121
Links to Exploration step
pubmed:22095533Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana.</title>
<author><name sortKey="Sagoe, Kwamena William Coleman" sort="Sagoe, Kwamena William Coleman" uniqKey="Sagoe K" first="Kwamena William Coleman" last="Sagoe">Kwamena William Coleman Sagoe</name>
<affiliation wicri:level="3"><nlm:affiliation>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School, Accra, Ghana. kwcsagoe@chs.edu.gh</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School, Accra</wicri:regionArea>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Agyei, Afrakoma Adjoa" sort="Agyei, Afrakoma Adjoa" uniqKey="Agyei A" first="Afrakoma Adjoa" last="Agyei">Afrakoma Adjoa Agyei</name>
</author>
<author><name sortKey="Ziga, Francesca" sort="Ziga, Francesca" uniqKey="Ziga F" first="Francesca" last="Ziga">Francesca Ziga</name>
</author>
<author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name>
<affiliation><country>Ghana</country>
<placeName><settlement type="city">Accra</settlement>
<settlement type="town">Legon (Ghana)</settlement>
<region type="region">Région du Grand Accra</region>
</placeName>
<orgName type="university" n="3">Université du Ghana</orgName>
</affiliation>
</author>
<author><name sortKey="Adiku, Theophilus K" sort="Adiku, Theophilus K" uniqKey="Adiku T" first="Theophilus K" last="Adiku">Theophilus K. Adiku</name>
</author>
<author><name sortKey="Seshi, Makafui" sort="Seshi, Makafui" uniqKey="Seshi M" first="Makafui" last="Seshi">Makafui Seshi</name>
</author>
<author><name sortKey="Arens, Max Q" sort="Arens, Max Q" uniqKey="Arens M" first="Max Q" last="Arens">Max Q. Arens</name>
</author>
<author><name sortKey="Mingle, Julius Abraham Addo" sort="Mingle, Julius Abraham Addo" uniqKey="Mingle J" first="Julius Abraham Addo" last="Mingle">Julius Abraham Addo Mingle</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22095533</idno>
<idno type="pmid">22095533</idno>
<idno type="doi">10.1002/jmv.22262</idno>
<idno type="wicri:Area/PubMed/Corpus">000121</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000121</idno>
<idno type="wicri:Area/PubMed/Curation">000121</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000121</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000121</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000121</idno>
<idno type="wicri:Area/Ncbi/Merge">000464</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana.</title>
<author><name sortKey="Sagoe, Kwamena William Coleman" sort="Sagoe, Kwamena William Coleman" uniqKey="Sagoe K" first="Kwamena William Coleman" last="Sagoe">Kwamena William Coleman Sagoe</name>
<affiliation wicri:level="3"><nlm:affiliation>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School, Accra, Ghana. kwcsagoe@chs.edu.gh</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School, Accra</wicri:regionArea>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Agyei, Afrakoma Adjoa" sort="Agyei, Afrakoma Adjoa" uniqKey="Agyei A" first="Afrakoma Adjoa" last="Agyei">Afrakoma Adjoa Agyei</name>
</author>
<author><name sortKey="Ziga, Francesca" sort="Ziga, Francesca" uniqKey="Ziga F" first="Francesca" last="Ziga">Francesca Ziga</name>
</author>
<author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name>
<affiliation><country>Ghana</country>
<placeName><settlement type="city">Accra</settlement>
<settlement type="town">Legon (Ghana)</settlement>
<region type="region">Région du Grand Accra</region>
</placeName>
<orgName type="university" n="3">Université du Ghana</orgName>
</affiliation>
</author>
<author><name sortKey="Adiku, Theophilus K" sort="Adiku, Theophilus K" uniqKey="Adiku T" first="Theophilus K" last="Adiku">Theophilus K. Adiku</name>
</author>
<author><name sortKey="Seshi, Makafui" sort="Seshi, Makafui" uniqKey="Seshi M" first="Makafui" last="Seshi">Makafui Seshi</name>
</author>
<author><name sortKey="Arens, Max Q" sort="Arens, Max Q" uniqKey="Arens M" first="Max Q" last="Arens">Max Q. Arens</name>
</author>
<author><name sortKey="Mingle, Julius Abraham Addo" sort="Mingle, Julius Abraham Addo" uniqKey="Mingle J" first="Julius Abraham Addo" last="Mingle">Julius Abraham Addo Mingle</name>
</author>
</analytic>
<series><title level="j">Journal of medical virology</title>
<idno type="eISSN">1096-9071</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Anti-HIV Agents (administration & dosage)</term>
<term>Antiretroviral Therapy, Highly Active (methods)</term>
<term>CD4 Lymphocyte Count</term>
<term>Coinfection (epidemiology)</term>
<term>Comorbidity</term>
<term>Female</term>
<term>Ghana</term>
<term>HIV Infections (complications)</term>
<term>HIV Infections (drug therapy)</term>
<term>HIV Infections (virology)</term>
<term>HIV-1 (isolation & purification)</term>
<term>Hepatitis B (complications)</term>
<term>Hepatitis B (epidemiology)</term>
<term>Hepatitis B Surface Antigens (blood)</term>
<term>Hepatitis C (complications)</term>
<term>Hepatitis C (epidemiology)</term>
<term>Hepatitis C Antibodies (blood)</term>
<term>Humans</term>
<term>Immunoglobulin M (blood)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Viral Load</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Agents antiVIH (administration et posologie)</term>
<term>Anticorps de l'hépatite C (sang)</term>
<term>Antigènes de surface du virus de l'hépatite B (sang)</term>
<term>Charge virale</term>
<term>Co-infection (épidémiologie)</term>
<term>Comorbidité</term>
<term>Femelle</term>
<term>Ghana</term>
<term>Humains</term>
<term>Hépatite B ()</term>
<term>Hépatite B (épidémiologie)</term>
<term>Hépatite C ()</term>
<term>Hépatite C (épidémiologie)</term>
<term>Immunoglobuline M (sang)</term>
<term>Infections à VIH ()</term>
<term>Infections à VIH (traitement médicamenteux)</term>
<term>Infections à VIH (virologie)</term>
<term>Mâle</term>
<term>Numération des lymphocytes CD4</term>
<term>Thérapie antirétrovirale hautement active ()</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (isolement et purification)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-HIV Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Hepatitis B Surface Antigens</term>
<term>Hepatitis C Antibodies</term>
<term>Immunoglobulin M</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Ghana</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents antiVIH</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term>
<term>Hepatitis B</term>
<term>Hepatitis C</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coinfection</term>
<term>Hepatitis B</term>
<term>Hepatitis C</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>HIV-1</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Antiretroviral Therapy, Highly Active</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps de l'hépatite C</term>
<term>Antigènes de surface du virus de l'hépatite B</term>
<term>Immunoglobuline M</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Co-infection</term>
<term>Hépatite B</term>
<term>Hépatite C</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>CD4 Lymphocyte Count</term>
<term>Comorbidity</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Viral Load</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Charge virale</term>
<term>Comorbidité</term>
<term>Femelle</term>
<term>Ghana</term>
<term>Humains</term>
<term>Hépatite B</term>
<term>Hépatite C</term>
<term>Infections à VIH</term>
<term>Mâle</term>
<term>Numération des lymphocytes CD4</term>
<term>Thérapie antirétrovirale hautement active</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Ghana</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Data on the effects of the presence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients co-infected with these viruses and HIV in West Africa are conflicting and little information is available in Ghana. A cohort of 138 treatment naïve individuals infected with HIV was screened for HBV and HCV serologic markers; HBsAg positive patients were tested for HBeAg, anti-HBe, and anti-HBc IgM. The viral load of HIV-1 in the plasma was determined in 81 patients. Eighteen of the 138 patients (13%) and 5 (3.6%) had HBsAg and anti-HCV, respectively. None of the patients had anti-HBc IgM, but 10 (55.6%) and 8 (44.4%) of the 18 patients who were HBsAg positive had HBeAg and anti-HBe, respectively. In patients with measurement of CD4(+) undertaken within 1 month (n = 83), CD4(+) count was significantly lower in patients with HBeAg (median [IQR], 81 [22-144]) as compared to those with anti-HBe (median [IQR], 210 [197-222]) (P = 0.002, CI: -96.46 to 51.21). However, those with HIV mono-infection had similar CD4(+) counts (median [IQR], 57 [14-159]) compared to those with HBeAg (P = 1.0, CI: -71.75 to 73.66). Similar results were obtained if CD4(+) count was measured within 2 months prior to initiation of HAART (n = 119). Generally, HBV and anti-HCV did not affect CD4(+) and viral loads of HIV-1 in plasma but patients with HIV and HBV co-infection who had HBeAg had more severe immune suppression as compared to those with anti-HBe. This may have implication for initiating HAART in HBV endemic areas.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22095533</PMID>
<DateCreated><Year>2011</Year>
<Month>11</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted><Year>2012</Year>
<Month>03</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2011</Year>
<Month>11</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>84</Volume>
<Issue>1</Issue>
<PubDate><Year>2012</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Journal of medical virology</Title>
<ISOAbbreviation>J. Med. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana.</ArticleTitle>
<Pagination><MedlinePgn>6-10</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.22262</ELocationID>
<Abstract><AbstractText>Data on the effects of the presence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients co-infected with these viruses and HIV in West Africa are conflicting and little information is available in Ghana. A cohort of 138 treatment naïve individuals infected with HIV was screened for HBV and HCV serologic markers; HBsAg positive patients were tested for HBeAg, anti-HBe, and anti-HBc IgM. The viral load of HIV-1 in the plasma was determined in 81 patients. Eighteen of the 138 patients (13%) and 5 (3.6%) had HBsAg and anti-HCV, respectively. None of the patients had anti-HBc IgM, but 10 (55.6%) and 8 (44.4%) of the 18 patients who were HBsAg positive had HBeAg and anti-HBe, respectively. In patients with measurement of CD4(+) undertaken within 1 month (n = 83), CD4(+) count was significantly lower in patients with HBeAg (median [IQR], 81 [22-144]) as compared to those with anti-HBe (median [IQR], 210 [197-222]) (P = 0.002, CI: -96.46 to 51.21). However, those with HIV mono-infection had similar CD4(+) counts (median [IQR], 57 [14-159]) compared to those with HBeAg (P = 1.0, CI: -71.75 to 73.66). Similar results were obtained if CD4(+) count was measured within 2 months prior to initiation of HAART (n = 119). Generally, HBV and anti-HCV did not affect CD4(+) and viral loads of HIV-1 in plasma but patients with HIV and HBV co-infection who had HBeAg had more severe immune suppression as compared to those with anti-HBe. This may have implication for initiating HAART in HBV endemic areas.</AbstractText>
<CopyrightInformation>Copyright © 2011 Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sagoe</LastName>
<ForeName>Kwamena William Coleman</ForeName>
<Initials>KW</Initials>
<AffiliationInfo><Affiliation>Clinical Virology Laboratory, Department of Microbiology, University of Ghana Medical School, Accra, Ghana. kwcsagoe@chs.edu.gh</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Agyei</LastName>
<ForeName>Afrakoma Adjoa</ForeName>
<Initials>AA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ziga</LastName>
<ForeName>Francesca</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lartey</LastName>
<ForeName>Margaret</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Adiku</LastName>
<ForeName>Theophilus K</ForeName>
<Initials>TK</Initials>
</Author>
<Author ValidYN="Y"><LastName>Seshi</LastName>
<ForeName>Makafui</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Arens</LastName>
<ForeName>Max Q</ForeName>
<Initials>MQ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Mingle</LastName>
<ForeName>Julius Abraham Addo</ForeName>
<Initials>JA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Med Virol</MedlineTA>
<NlmUniqueID>7705876</NlmUniqueID>
<ISSNLinking>0146-6615</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006514">Hepatitis B Surface Antigens</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018937">Hepatitis C Antibodies</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D023241" MajorTopicYN="N">Antiretroviral Therapy, Highly Active</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N" Type="Geographic">Ghana</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006509" MajorTopicYN="N">Hepatitis B</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006514" MajorTopicYN="N">Hepatitis B Surface Antigens</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018937" MajorTopicYN="N">Hepatitis C Antibodies</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year>
<Month>11</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2011</Year>
<Month>11</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2012</Year>
<Month>3</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">22095533</ArticleId>
<ArticleId IdType="doi">10.1002/jmv.22262</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Ghana</li>
</country>
<region><li>Région du Grand Accra</li>
</region>
<settlement><li>Accra</li>
<li>Legon (Ghana)</li>
</settlement>
<orgName><li>Université du Ghana</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Adiku, Theophilus K" sort="Adiku, Theophilus K" uniqKey="Adiku T" first="Theophilus K" last="Adiku">Theophilus K. Adiku</name>
<name sortKey="Agyei, Afrakoma Adjoa" sort="Agyei, Afrakoma Adjoa" uniqKey="Agyei A" first="Afrakoma Adjoa" last="Agyei">Afrakoma Adjoa Agyei</name>
<name sortKey="Arens, Max Q" sort="Arens, Max Q" uniqKey="Arens M" first="Max Q" last="Arens">Max Q. Arens</name>
<name sortKey="Mingle, Julius Abraham Addo" sort="Mingle, Julius Abraham Addo" uniqKey="Mingle J" first="Julius Abraham Addo" last="Mingle">Julius Abraham Addo Mingle</name>
<name sortKey="Seshi, Makafui" sort="Seshi, Makafui" uniqKey="Seshi M" first="Makafui" last="Seshi">Makafui Seshi</name>
<name sortKey="Ziga, Francesca" sort="Ziga, Francesca" uniqKey="Ziga F" first="Francesca" last="Ziga">Francesca Ziga</name>
</noCountry>
<country name="Ghana"><region name="Région du Grand Accra"><name sortKey="Sagoe, Kwamena William Coleman" sort="Sagoe, Kwamena William Coleman" uniqKey="Sagoe K" first="Kwamena William Coleman" last="Sagoe">Kwamena William Coleman Sagoe</name>
</region>
<name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000464 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000464 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= SidaGhanaV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:22095533 |texte= Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:22095533" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a SidaGhanaV1
This area was generated with Dilib version V0.6.31. |